{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+ALL&page=34", "query": { "condition": "Relapsed/Refractory ALL", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 3664, "total_pages": 367, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+ALL&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+ALL&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T23:07:23.274Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00800566", "title": "Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Oral Clofarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2008-11", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2012-08-01", "last_synced_at": "2026-11-11T23:07:23.274Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00800566" }, { "nct_id": "NCT05795595", "title": "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Cervical Carcinoma", "Esophageal Carcinoma", "Pancreatic Adenocarcinoma", "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "CTX131", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CRISPR Therapeutics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2023-03-13", "completion_date": "2025-09-18", "has_results": false, "last_update_posted_date": "2026-11-05", "last_synced_at": "2026-11-11T23:07:23.274Z", "location_count": 7, "location_summary": "Duarte, California • Chicago, Illinois • Boston, Massachusetts + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05795595" }, { "nct_id": "NCT02158975", "title": "Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, T-Cell" ], "interventions": [ { "name": "MLN9708", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2014-09", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-11-11T23:07:23.274Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02158975" }, { "nct_id": "NCT02715011", "title": "Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "JNJ-63709178", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2016-06-01", "completion_date": "2021-03-26", "has_results": false, "last_update_posted_date": "2021-08-31", "last_synced_at": "2026-11-11T23:07:23.274Z", "location_count": 7, "location_summary": "Detroit, Michigan • New York, New York • Charlotte, North Carolina + 4 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02715011" }, { "nct_id": "NCT03504644", "title": "Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent B Lymphoblastic Lymphoma", "Recurrent T Acute Lymphoblastic Leukemia", "Recurrent T Lymphoblastic Lymphoma", "Refractory B Acute Lymphoblastic Leukemia", "Refractory B Lymphoblastic Lymphoma", "Refractory T Acute Lymphoblastic Leukemia", "Refractory T Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vincristine Liposomal", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-08-13", "completion_date": "2028-12-31", "has_results": true, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-11T23:07:23.274Z", "location_count": 163, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 120 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03504644" }, { "nct_id": "NCT04696029", "title": "DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Medulloblastoma" ], "interventions": [ { "name": "Difluoromethylornithine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Giselle Sholler", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 118, "start_date": "2021-03-29", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-11-11T23:07:23.274Z", "location_count": 25, "location_summary": "Little Rock, Arkansas • Oakland, California • Sacramento, California + 22 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04696029" }, { "nct_id": "NCT05462639", "title": "Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab (PF-06863135)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-11-11T23:07:23.274Z", "location_count": 33, "location_summary": "Los Angeles, California • Orange, California • Miami, Florida + 16 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05462639" }, { "nct_id": "NCT02219737", "title": "Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CD20 Positive", "Recurrent Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2014-09-12", "completion_date": "2017-05-11", "has_results": false, "last_update_posted_date": "2018-01-26", "last_synced_at": "2026-11-11T23:07:23.274Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02219737" }, { "nct_id": "NCT04030195", "title": "Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma, Relapsed", "Chronic Lymphoid Leukemia in Relapse", "Non-Hodgkin's Lymphoma Refractory", "Chronic Lymphocytic Leukemia", "Lymphoma, Non-Hodgkin", "Leukemia, Lymphocytic, Chronic", "B-cell Chronic Lymphocytic Leukemia", "B-cell Non Hodgkin Lymphoma", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "PBCAR20A", "type": "GENETIC" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Precision BioSciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2020-03-24", "completion_date": "2021-06-24", "has_results": true, "last_update_posted_date": "2023-01-31", "last_synced_at": "2026-11-11T23:07:23.274Z", "location_count": 5, "location_summary": "Duarte, California • Stanford, California • New York, New York + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04030195" }, { "nct_id": "NCT00628732", "title": "A Pharmacokinetic Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Cyclophosphamide and Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Medical Center Dallas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 36, "start_date": "2005-01", "completion_date": "2007-02", "has_results": false, "last_update_posted_date": "2009-01-28", "last_synced_at": "2026-11-11T23:07:23.274Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00628732" } ] }